Lekamwasam, S., Adachi, J. D, Agnusdei, D., Bilezikian, J. P, Boonen, S., Borgström, F., Cooper, C., Perez, A. D, Eastell, R., Hofbauer, L. C, Kanis, J. A, Langdahl, B. L, Lesnyak, O., Lorenc, R. S, McCloskey, E., Messina, O. D, Napoli, N., Obermayer-Pietsch, B., Ralston, S. H, Sambrook, P. N, Silverman, S., Sosa, M., Stepan, J. J, Suppan, G., Wahl, D. A & Compston, JE. (2012). An appendix to the 2012 IOF-ECTS guidelines for the management of glucocorticoid-induced osteoporosis. Archives of Osteoporosis,7(2017-02-01), 25-30. United Kingdom: Springer UK. Retrieved from https://doi.org/10.1007/s11657-012-0070-7
The use of glucocorticoids in the treatment of medical disorders can lead to rapid bone loss and increased risk of fragility fracture. Updated clinical guidelines are needed that accommodate recent advances in fracture risk assessment and new pharmacological interventions to reduce fracture risk. This document serves as an appendix to the 2012 IOF–ECTS guidelines for the management of glucocorticoid-induced osteoporosis.
Institute for Health and Ageing
Access may be restricted.